Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma

Disease Markers

Volumn 35, Issue 4, 2013, Pages 261-266

  Honkavuori Toivola, Maria ^a   Santala, Markku ^a   Soini, Ylermi ^a,b   Turpeenniemi Hujanen, Taina ^a   Talvensaari Mattila, Anne ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; PARAFFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84884946707     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/416870     Document Type: Article

References (24)

1. Chirco R., Liu X. W., Jung K. K., Kim H. R. C., Novel functions of TIMPs in cell signaling. Cancer and Metastasis Reviews 2006 25 1 99 113 2-s2.0-33646541350 10.1007/s10555-006-7893-x
2. Lambert E., Dassé E., Haye B., Petitfrère E., TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology 2004 49 3 187 198 2-s2.0-1342279517 10.1016/j.critrevonc.2003.09.008
3. Bourboulia D., Stetler-Stevenson W. G., Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Seminars in Cancer Biology 2010 20 3 161 168 2-s2.0-77956301181 10.1016/j.semcancer.2010.05.002
4. Şurlin V., Ioana M., Pleşea I. E., Genetic patterns of metalloproteinases and their tissular inhibitors-clinicopathologic and prognostic significance in colorectal cancer. Romanian Journal of Morphology and Embryology 2011 52 1 231 236 2-s2.0-79953151406
5. Sogawa K., Kondo K., Fujino H., Takahashi Y., Miyoshi T., Sakiyama S., Mukai K., Monden Y., Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 2003 98 9 1822 1829 2-s2.0-0142243216 10.1002/cncr.11725
6. Honkavuori M., Talvensaari-Mattila A., Soini Y., Turpeenniemi-Hujanen T., Santala M., MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecologic Oncology 2007 104 1 217 221 2-s2.0-33846030501 10.1016/j.ygyno.2006.08.006
7. Ruokolainen H., Pääkkö P., Turpeenniemi-Hujanen T., Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clinical Cancer Research 2004 10 9 3110 3116 2-s2.0-2442428314 10.1158/1078-0432.CCR-03-0530
8. Talvensaari-Mattila A., Pääkkö P., Turpeenniemi-Hujanen T., Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Teh British Journal of Cancer 2003 89 7 1270 1275 2-s2.0-0242266487 10.1038/sj.bjc.6601238
9. Sienel W., Hellers J., Morresi-Hauf A., Lichtinghagen R., Mutschler W., Jochum M., Klein C., Passlick B., Pantel K., Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. International Journal of Cancer 2003 103 5 647 651 2-s2.0-0037455842 10.1002/ijc.10841
10. Stamenkovic I., Extracellular matrix remodelling: the role of matrix metalloproteinases. Journal of Pathology 2003 200 4 448 464 2-s2.0-0038575443 10.1002/path.1400
11. Stetler-Stevenson W. G., The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer and Metastasis Reviews 2008 27 1 57 66 2-s2.0-38549125513 10.1007/s10555-007-9105-8
12. Honkavuori-Toivola M., Talvensaari-Mattila A., Soini Y., Turpeenniemi-Hujanen T., Santala M., Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. Tumour Biology 2012 33 4 935 941 10.1007/s13277-012-0321-7
13. Tamakoshi K., Kikkawa F., Nawa A., Ishikawa H., Mizuno K., Tamakoshi A., Yamagata S., Suganuma N., Tomoda Y., Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 1995 76 12 2565 2571 10.1002/1097-0142(19951215)76:12<2565::AID-CNCR2820761224>3.0. CO;2-B
14. Park D. W., Ryu H. S., Choi D. S., Park Y. H., Chang K. H., Min C. K., Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecologic Oncology 2001 82 3 442 449 2-s2.0-0034824366 10.1006/gyno.2001.6294
15. Kamat A. A., Fletcher M., Gruman L. M., Mueller P., Lopez A., Landen C. N. Jr., Han L., Gershenson D. M., Sood A. K., The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clinical Cancer Research 2006 12 6 1707 1714 2-s2.0-33645676359 10.1158/1078-0432.CCR-05-2338
16. Vasala K., Pääkkö P., Turpeenniemi-Hujanen T., Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003 62 5 952 957 2-s2.0-0242495736 10.1016/S0090-4295(03)00660- 5
17. Alakus H., Grass G., Hennecken J. K., Bollschweiler E., Schulte C., Drebber U., Baldus S. E., Metzger R., Hölscher A. H., Mönig S. P., Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histology and Histopathology 2008 23 8 917 923 2-s2.0-46249122672
18. Hilska M., Roberts P. J., Collan Y. U., Laine V. J. O., Kössi J., Hirsimäki P., Rahkonen O., Laato M., Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. International Journal of Cancer 2007 121 4 714 723 2-s2.0-34547138889 10.1002/ijc.22747
19. Moser P. L., Hefler L., Tempfer C., Neunteufel W., Kieback D. G., Gitsch G., Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Research 1999 19 3 2365 2367 2-s2.0-0032774472
20. Ueno H., Yamashita K., Azumano I., Inoue M., Okada Y., Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. International Journal of Cancer 1999 84 5 470 477 2-s2.0-0033595649
21. Shaco-Levy R., Sharabi S., Piura B., Sion-Vardy N., MMP-2, TIMP-1, E-cadherin, and β -catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstetricia et Gynecologica Scandinavica 2008 87 8 868 874 2-s2.0-49649096620 10.1080/00016340802253775
22. Graesslin O., Cortez A., Uzan C., Birembaut P., Quereux C., Daraï E., Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. International Journal of Gynecological Cancer 2006 16 5 1911 1917 2-s2.0-33749152996 10.1111/j.1525-1438. 2006.00717.x
23. Monaghan H., MacWhinnie N., Williams A. R. W., The role of matrix metalloproteinases-2, -7 and -9 and β -catenin in high grade endometrial carcinoma. Histopathology 2007 50 3 348 357 2-s2.0-33846510526 10.1111/j.1365-2559.2007.02612.x
24. Graesslin O., Cortez A., Fauvet R., Lorenzato M., Birembaut P., Daraï E., Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Annals of Oncology 2006 17 4 637 645 2-s2.0-33645312651 10.1093/annonc/mdj129